依达拉奉治疗急性缺血性小卒中患者血清NSE含量变化的临床观察  

Talking Clinical Observation of Serum NSE Concentration Changes in Patients Taking Edaravone with Acute Ischemic Minor Stroke

作　　者：解学军[1] 赵艳茹[1] 

机构地区：[1]赤峰学院附属医院神经内二科,内蒙古赤峰024000

出　　处：《内蒙古医学杂志》2014年第4期414-416,共3页Inner Mongolia Medical Journal

摘　　要：目的探讨依达拉奉治疗急性缺血性小卒中的脑保护作用。方法将缺血性小卒中患者随机分为研究组及对照组;对照组研究对象给予阿司匹林、辛伐他汀、银杏达莫、胞二磷胆碱基础治疗,研究组研究对象基础治疗再加用依达拉奉(0.9%的氯化钠注射液100 ml+依达拉奉注射液30 ml,2次/d)。所有患者以2周为1个疗程。结果与治疗前比较,两组血清NSE浓度均显著降低,差异均有统计学意义(P<0.05),但治疗2周后血清NSE浓度的降低幅度与对照组比较,差异无统计学意义(P>0.05)。结论依达拉奉可能有效降低血清NSE浓度,但在治疗急性缺血小卒中过程中非临床必用药物。Objective Discussion on the cerebral protective effects of edaravone in the treatment of acuteischemic minor stroke. Method Ischemic minor stroke patients were randomly divided into experimental group and control group; The control subjects were given basic treatment, including aspirin, simvastatin, Yinxingdamo, citicoline; the study group subjects were received basic treatment while giving edaravone（0.9 % sodium chloride injection 100ml ＋ edaravone injection 30 ml 2 times/d）. All patients were treated 2 weeks. Results all subjects of serum NSE concentration were significantly reduced than that of before treatment, （P 〈 0.05）, But reduced amplitude of serum NSE concentrations were not statistically significant than that of the control group after two weeks of treatment（P 〉0.05）. Conclusion Edaravone may effectively reduce serum NSE concentrations , but it must not be used in the clinical treatment of acute ischemic minor stroke.

关 键 词：依达拉奉 小卒中 神经元烯醇化酶 

分 类 号：R743.3[医药卫生—神经病学与精神病学]